Hautarztpraxis Dr. Leitz Und Kollegen

The site is conducting research focused on hormone‑related hair loss in women, aiming to assess new oral and topical therapies that promote hair growth.

• Evaluation of oral treatments for female androgenetic alopecia
• Assessment of topical solutions combined with systemic therapy
• Safety and patient‑reported outcome monitoring
• Impact on hair density and quality over six months
• Comparison with standard placebo regimens

Located in Stuttgart, the clinic’s two investigators are overseeing these studies as part of a broader portfolio of eight trials.

Clinical work at the practice includes trials targeting autoimmune skin disorders, such as bullous pemphigoid, chronic spontaneous urticaria, and nonsegmental vitiligo, to test innovative biologic and small‑molecule therapies.

• Testing of dupilumab for sustained remission in bullous pemphigoid
• Ritlecitinib evaluation for chronic urticaria symptom control
• Long‑term safety study of ritlecitinib in vitiligo patients
• Assessment of disease activity scores and quality‑of‑life measures
• Monitoring of immunologic biomarkers during treatment

The research contributes to advancing therapeutic options for patients with immune‑mediated dermatologic conditions.

The clinic’s portfolio features investigations into chronic plaque psoriasis and other skin disorders, exploring the effectiveness of targeted biologics in pediatric and adult populations.

• Guselkumab safety and efficacy in children with plaque psoriasis
• Impact of treatment on skin clearance and symptom relief
• Longitudinal follow‑up to assess durability of response
• Evaluation of patient‑centered outcomes such as itching and discomfort
• Integration of dermatologic assessments with overall health status

By including both younger and older participants, the studies aim to broaden therapeutic options across age groups.

Research at the site includes trials of novel mRNA vaccines designed to prevent viral infections such as influenza and cytomegalovirus, focusing on immunogenicity and safety in healthy volunteers.

• Evaluation of an influenza vaccine candidate in adults over 50
• Assessment of vaccine efficacy against laboratory‑confirmed influenza-like illness
• Study of a CMV vaccine to prevent primary infection in seronegative women
• Monitoring of reactogenicity and short‑term safety across dosing schedules
• Measurement of immune response markers post‑vaccination

These investigations support the development of next‑generation vaccines for common viral threats.

Beyond disease‑specific studies, the practice conducts a range of trials that span multiple therapeutic areas, emphasizing novel therapies, safety profiling, and patient‑focused outcomes.

• Multi‑disciplinary studies combining dermatology and virology
• Pediatric and adolescent participation in targeted therapy trials
• Comprehensive safety monitoring across diverse treatment modalities
• Evaluation of quality‑of‑life improvements alongside clinical endpoints
• Collaboration with external research networks to enhance trial diversity

With eight active trials and a dedicated team of two investigators, the site remains a hub for innovative clinical research in Stuttgart.